Qiagen (NYSE:QGEN) Given New $48.00 Price Target at UBS Group

Qiagen (NYSE:QGEN) had its price objective trimmed by UBS Group from $50.00 to $48.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other research analysts also recently issued reports on QGEN. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price target (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Morgan Stanley restated an “equal weight” rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price target on the stock. in a research report on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $48.78.

Qiagen Stock Down 2.6 %

Shares of NYSE QGEN opened at $41.34 on Friday. The stock has a market capitalization of $9.17 billion, a price-to-earnings ratio of 115.09, a price-to-earnings-growth ratio of 3.29 and a beta of 0.36. Qiagen has a 52 week low of $40.15 and a 52 week high of $49.30. The firm has a 50-day moving average price of $43.78 and a 200 day moving average price of $43.29. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.97% and a net margin of 4.23%. Equities research analysts anticipate that Qiagen will post 2.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Qiagen

Institutional investors and hedge funds have recently modified their holdings of the company. Sanctuary Advisors LLC purchased a new stake in Qiagen in the 2nd quarter worth approximately $647,000. Park Avenue Securities LLC purchased a new stake in shares of Qiagen in the third quarter valued at $304,000. GAMMA Investing LLC increased its stake in Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the last quarter. CWM LLC lifted its position in Qiagen by 11.5% during the third quarter. CWM LLC now owns 2,792 shares of the company’s stock worth $127,000 after buying an additional 287 shares during the period. Finally, Creative Planning boosted its stake in Qiagen by 12.7% in the 3rd quarter. Creative Planning now owns 40,571 shares of the company’s stock worth $1,849,000 after buying an additional 4,561 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.